EAACI Congress 2025
BackL-TPS07 - Biologicals 04
Friday 13 Jun, 12:00 PM -
13:00 PM Glasgow, United Kingdom
Poster Zone
Thematic Poster Session
"The Role of Atopy Biomarkers in Predicting Dupilumab Response in Moderate to Severe Atopic Dermatitis: A Single Center Retrospective Study"
A 3-Year Follow-Up of Severe Atopic Dermatitis and Atopic Keratoconjunctivitis Treated with Upadacitinib
AllergoOncology: Generation of Equinized Anti-PD-L1 mAbs with Specific Equine Constant Regions by MOE-PCR Ligation-Independent Cloning (LIC)
Berotralstat effectively controls a type 2 Hereditary Angioedema patient, refractory to other long-term prophylaxis treatments – Case report
Ciclosporin for omalizumab-refractory CSU in a Paediatric population in Cork University Hospital: a case series
Differential effects of dupilumab in women with severe uncontrolled asthma
Dupilumab Treatment Effects on Atopic Manifestations in Patients with Inborn Errors of Immunity
Emerging inmunomodulatory agents for atopic dermatitis
Evaluating the efficacy of dupilumab treatment for atopic dermatitis across geographic areas: A systematic review and meta-regression analysis
Evaluation of the Effectiveness of Omalizumab in Treating Cypress Pollen Allergic Rhinoconjunctivitis with Total IgE Levels Below 30IU/ml
Impact of dupilumab on allergen specific immunoglobulin E production
Long-term Prophylaxis with Lanadelumab in Hereditary and Acquired Angioedema: A Single-Center Retrospective-Prospective “Real-Life” Analysis
Nonimmediate hypersensitivity reaction to Lanadelumab in a patient with Hereditary Angioedema: a case report
Omalizumab Use in Pediatric Chronic Urticaria, A Retrospective Study from a Tertiary Hospital
Potential blood biomarkers of disease activity in patients with chronic spontaneous urticaria
Quicker EASI 75 or greater decline of DLQI - is it significant? Comparison of dupilumab treatment among children and adults in two centres in Cracow
